文献速递泌尿男性生殖肿瘤

STAMPEDE试验:多西他赛联合内分泌治疗用于高/低肿瘤负荷转移性激素敏感前列腺癌的长期生存结果

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial.
PubMed 文献 · Ann Oncol · 2019-01-01

STAMPEDE试验长期随访显示,转移性激素初治前列腺癌患者在内分泌治疗基础上加用多西他赛可显著改善总生存(HR=0.81,95%CI 0.69-0.95,P=0.009),且获益与转移负荷亚组间无交互作用(交互P=0.827)。无进展生存和失败-free生存亦显著改善,1年后≥3级毒性两组相近(28% vs 27%)。

要点

  • 多西他赛联合内分泌治疗显著改善M1患者总生存(HR=0.81,P=0.009)。
  • 多西他赛获益与转移负荷高低无显著交互作用(交互P=0.827)。
  • 长期随访未发现多西他赛增加1年后≥3级毒性(28% vs 27%)。

核心结论

  • 在内分泌治疗基础上加用多西他赛对转移性激素初治前列腺癌患者的总生存获益在长期随访中持续存在。
  • 多西他赛的生存获益在不同转移负荷亚组间无显著差异,推荐无论转移负荷高低均可考虑 upfront 多西他赛。

研究设计与样本

  • 随机对照试验,按2:1比例将M1患者分配至标准治疗(SOC)组或SOC+多西他赛组。
  • 2005年10月5日至2013年3月31日共随机1086例M1患者,SOC组724例,SOC+多西他赛组362例。
  • 转移负荷基于可获得的回顾性基线分期扫描评估,830/1086(76%)患者可评估,其中低负荷362例(44%),高负荷468例(56%)。
  • 中位随访78.2个月。

主要发现

  • SOC组死亡494例(较前次报告多41%)。
  • 总生存:多西他赛组对比SOC组HR=0.81(95%CI 0.69-0.95,P=0.009),转移负荷亚组间交互P=0.827。
  • 失败-free生存:HR=0.66(95%CI 0.57-0.76,P<0.001),亚组间交互P>0.5。
  • 无进展生存:HR=0.69(95%CI 0.59-0.81,P<0.001),亚组间交互P>0.5。
  • 1年后≥3级毒性:SOC组28%,多西他赛组27%(限于1年时仍在随访且未进展的患者),无证据显示多西他赛导致晚期毒性。

临床怎么用

  • 对于转移性激素初治前列腺癌患者,无论转移负荷高低,均应考虑在内分泌治疗基础上加用多西他赛。
  • 长期随访支持 upfront 多西他赛作为该人群的标准治疗选择之一。

局限性

  • 转移负荷评估基于回顾性收集的基线分期扫描,仅76%患者可评估。
  • 转移负荷亚组分析为回顾性分类,可能存在选择偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients starting long-term androgen deprivation therapy. We report on long-term outcomes stratified by metastatic burden for M1 patients. METHODS: We randomly allocated patients in 2 : 1 ratio to standard-of-care (SOC; control group) or SOC + docetaxel. Metastatic disease burden was categorised using retrospectively-collected baseline staging scans where available. Analysis used Cox regression models, adjusted for stratification factors, with emphasis on restricted mean survival time where hazards were non-proportional. RESULTS: Between 05 October 2005 and 31 March 2013, 1086 M1 patients were randomised to receive SOC (n = 724) or SOC + docetaxel (n = 362). Metastatic burden was assessable for 830/1086 (76%) patients; 362 (44%) had low and 468 (56%) high metastatic burden. Median follow-up was 78.2 months. There were 494 deaths on SOC (41% more than the previous report). There was good evidence of benefit of docetaxel over SOC on OS (HR = 0.81, 95% CI 0.69-0.95, P = 0.009) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P = 0.827). Analysis of other outcomes found evidence of benefit for docetaxel over SOC in failure-free survival (HR = 0.66, 95% CI 0.57-0.76, P < 0.001) and progression-free survival (HR = 0.69, 95% CI 0.59-0.81, P < 0.001) with no evidence of heterogeneity of docetaxel effect between metastatic burden sub-groups (interaction P > 0.5 in each case). There was no evidence that docetaxel resulted in late toxicity compared with SOC: after 1 year, G3-5 toxicity was reported for 28% SOC and 27% docetaxel (in patients still on follow-up at 1 year without prior progression). CONCLUSIONS: The clinically significant benefit in survival for upfront docetaxel persists at longer follow-up, with no evidence that benefit differed by metastatic burden. We advocate that upfront docetaxel is considered for metastatic hormone naïve prostate cancer patients regardless of metastatic burden.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019. PMID: 31560068. doi:10.1093/annonc/mdz396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。